Nizar Dholakia
Infectious Disease · Bellaire, TXNPI 1609824358
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,015 of the $28,800 with a category attached, or 69.5%. Paratek Pharmaceuticals, Inc. accounts for 91.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $15,230 and has fallen 99.8% since, to $25 in 2024. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $129.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$26K
- Melinta Therapeutics, LLC$795
- Insmed, Inc.$571
- Merck$287
- Shionogi Inc$262
- Janssen Products, LP$145
- plus $540 from 9 others
What the payments were for
- Speaking & faculty fees$20,01569%
- Travel & lodging$3,89614%
- Food & beverage$4,61416%
- Education$2751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 100 | $26,199 |
| Melinta Therapeutics, LLC | 39 | $795 |
| Insmed, Inc. | 22 | $571 |
| Merck | 18 | $287 |
| Shionogi Inc | 14 | $262 |
| Janssen Products, LP | 2 | $145 |
| Johnson & Johnson | 6 | $107 |
| Cipla USA Inc. | 1 | $95 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Gilead | 3 | $58 |
| AbbVie | 4 | $53 |
| Philips North America LLC | 3 | $49 |
| Eisai Inc. | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,800 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 17 | $12,602 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,681 |
| EliquisApixaban | 22 | $10,378 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,694 |
| Aripiprazole | 18 | $826 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $730 |
| Atorvastatin Calcium | 122 | $453 |
| Trazodone Hcl | 46 | $382 |
| Gabapentin | 53 | $379 |
| Methocarbamol | 32 | $362 |
| Omeprazole | 33 | $313 |
| Quetiapine Fumarate | 28 | $260 |
| Baclofen | 18 | $260 |
| Metoprolol Succinate | 28 | $226 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 32 | $198 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Bellaire
- Elizabeth RaceDallas$1.5M
- Ogechika AlozieEl Paso$834K
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Cedric SpakFort Worth$427K
- Ben BarnettHouston$424K
- Uriel SandkovskyDallas$320K
- Amar SafdarHouston$284K
- Roger BedimoDallas$269K
- Miguel Sierra-HoffmanVictoria$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.